Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females

J Clin Oncol. 2008 Jul 10;26(20):3468; author reply 3468-9. doi: 10.1200/JCO.2008.17.6479.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Cohort Studies
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / mortality
  • Female
  • Fluorouracil / therapeutic use*
  • Humans
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Methylenetetrahydrofolate Reductase (NADPH2) / metabolism
  • Middle Aged
  • Polymorphism, Genetic*
  • Predictive Value of Tests
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Fluorouracil